

## Statement of Advice:

**bevacizumab (Avastin<sup>®</sup>) 25 mg/ml concentrate for solution for infusion**  
**(No: 1190/16)**

**Roche Products Ltd**

05 August 2016

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation

**bevacizumab (Avastin<sup>®</sup>)** is not recommended for use within NHS Scotland.

**Indication under review:** In combination with erlotinib for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman,  
Scottish Medicines Consortium**